EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers

Sara E Berman, Andrew D Siderowf

Cells · 18.08.2025 · 14 (16) · 1272

DOI: 10.3390/cells14161272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 18.08.2025. Verfasst von Sara E Berman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Disease and Movement Disorders Center, Department of Neurology, Pennsylvania Hospital, Perelman School of Medicine, University of Pennsyl…. Hauptthemen laut MEDLINE: alpha-Synuclein, Positron-Emission Tomography, Biomarkers, Synucleinopathies. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synucleinopathies are neurodegenerative disorders defined by the pathological aggregation of α-synuclein. Several α-synuclein biomarkers have been developed to aid diagnosis and research, such as cerebrospinal fluid (CSF) and blood-based measurements, seed amplification assays (SAAs), and immunohistochemical detection from skin biopsies. While these existing biomarkers have important uses, they face limitations in diagnostic specificity, spatial localization, and the ability to monitor disease progression or response to therapy. The development of α-synuclein PET tracers, which would allow for the direct in vivo imaging of α-synuclein, represents an important unmet need in both research and the clinical care of patients with movement disorders. This review outlines the current landscape of α-synuclein biomarkers and discusses both the scientific and technical challenges in developing α-synuclein PET imaging tracers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinPositron-Emission TomographyBiomarkersSynucleinopathiesHumansAnimals

Stichwörter der Autor:innen

Parkinson’s diseasedementia with Lewy Bodiesα-synuclein

Substanzen

alpha-SynucleinBiomarkers

Autor:innen und Institutionen

  • Parkinson's Disease and Movement Disorders Center, Department of Neurology, Pennsylvania Hospital, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Förderung

  • NINDS NIH HHS
  • NIH

Zitieren

APA

Berman, S. E., & Siderowf, A. D. (2025). Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers. Cells, 14(16), 1272. https://doi.org/10.3390/cells14161272

Vancouver

Berman SE, Siderowf AD. Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers. Cells. 2025;14(16):1272. doi:10.3390/cells14161272

BibTeX
@article{Berman2025,
  author = {Berman, Sara E and Siderowf, Andrew D},
  title = {Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {16},
  pages = {1272},
  doi = {10.3390/cells14161272}
}
Kostenlos starten →